| Popis: |
Head and neck cancer is the seventh common cancer in the world, and various existing treatment strategies provide modest benefit for most patients with head and neck cancer. Meanwhile, therapeutic strategies lacking molecular typing significantly hinder the development of individualized treatment for head and neck cancer. In recent years, connected by preclinical models, the novel ideal has gradually reached a consensus in terms of facilitating inter-transformation of clinical problems and basic achievements. As a bridge between basic research and clinical transformation, patient-derived xenografts (PDX) models precisely replicate genetic characteristics and tumor evolution, which are displaying great vitality in elucidating the mechanism of tumorigenesis and progression. Moreover, cohorts composed of several PDX models highlight the unique advantages of mice for drug screening and biomarker analysis for patients. This ideal preclinical model explores potential treatment strategies suited the ethical standards as much as possible for patients.头颈癌位居全球第七大恶性肿瘤，现存多种治疗策略无法满足大部分患者的临床获益需求。同时，缺乏分子分型指导的头颈癌治疗策略也严重阻碍个性化疗法的发展。近年来，以临床前模型为纽带，加快临床问题与基础成果双向转化的新思路逐渐成为业界共识。PDX模型作为肿瘤基础研究和临床转化的桥梁，能够精准复制肿瘤遗传特征和肿瘤进化，在阐析肿瘤发生发展机制中显示出强大的生命力。借助PDX模型组成的治疗队列，彰显出小鼠为患者进行药物筛选和生物标志物分析的独特优势，这种理想的临床前模型能够在符合伦理范畴内最大可能的为患者寻找潜在的治疗策略。. |
